Aarti Drugs Ltd
NSE:AARTIDRUGS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
321.75
545.05
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Aarti Drugs Ltd
Net Income (Common)
Aarti Drugs Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Aarti Drugs Ltd
NSE:AARTIDRUGS
|
Net Income (Common)
₹2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
10%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Net Income (Common)
₹57.7B
|
CAGR 3-Years
23%
|
CAGR 5-Years
29%
|
CAGR 10-Years
15%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Net Income (Common)
₹54.4B
|
CAGR 3-Years
28%
|
CAGR 5-Years
24%
|
CAGR 10-Years
12%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Net Income (Common)
₹104.5B
|
CAGR 3-Years
37%
|
CAGR 5-Years
48%
|
CAGR 10-Years
14%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Net Income (Common)
₹43.2B
|
CAGR 3-Years
299%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
7%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Net Income (Common)
₹21.4B
|
CAGR 3-Years
39%
|
CAGR 5-Years
12%
|
CAGR 10-Years
4%
|
|
Aarti Drugs Ltd
Glance View
Aarti Drugs Ltd. engages in the development, manufacture and market of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 1,450 full-time employees. The Company, through its wholly-owned subsidiary Pinnacle Life Science Private Limited, is focused on producing formulations. The Company’s products under APIs include Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole and Ofloxacin. Its pharma intermediates products are Tinidazole, Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide and Raloxifene. The company also offers specialty chemicals, such as Benzene Sulphonyl Chloride and Methyl Nicotinate. The Company’s products under development include Alcoholism Treatment, Anticoagulant, Antihyperphosphatemia, Anti-cholestrol, Cardiovascular, Cardiprotectant and Antidiabetic.
See Also
What is Aarti Drugs Ltd's Net Income (Common)?
Net Income (Common)
2B
INR
Based on the financial report for Sep 30, 2025, Aarti Drugs Ltd's Net Income (Common) amounts to 2B INR.
What is Aarti Drugs Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
10%
Over the last year, the Net Income (Common) growth was 31%. The average annual Net Income (Common) growth rates for Aarti Drugs Ltd have been 2% over the past three years , -4% over the past five years , and 10% over the past ten years .